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Abstract
Rationale Impairments in attention and inhibitory control are
endophenotypicmarkers of neuropsychiatric disorders such as
schizophrenia and represent key targets for therapeutic man-
agement. Robust preclinical models and assays sensitive to
clinically relevant treatments are crucial for improving cogni-
tive enhancement strategies.
Objectives We assessed a rodent model with neural and be-
havioral features relevant to schizophrenia (gestational day 17
methylazoxymethanol acetate treatment (MAM-E17)) on a
novel test of attention and executive function, and examined
the impact of putative nootropic drugs.
Methods MAM-E17 and sham control rats were trained on a
novel touchscreen-based rodent continuous performance test
(rCPT) designed to closely mimic the human CPT paradigm.
Performance following acute, systemic treatment with an array
of pharmacological compounds was investigated.
Results Two cohorts of MAM-E17 rats were impaired on
rCPT performance including deficits in sensitivity (d′) and
increased false alarm rates (FARs). Sulpiride (0–30 mg/kg)
dose-dependently reduced elevated FAR in MAM-E17 rats
whereas low-dose modafinil (8 mg/kg) only improved d′ in
sham controls. ABT-594 (5.9–19.4 μg/kg) and modafinil
(64 mg/kg) showed expected stimulant-like effects, while
LSN2463359 (5 mg/kg), RO493858 (10 mg/kg), atomoxetine
(0.3–1 mg/kg), and sulpiride (30 mg/kg) showed expected
suppressant effects on performance across all animals.
Donepezil (0.1–1 mg/kg) showed near-significant enhance-
ments in d′, and EVP-6124 (0.3–3 mg/kg) exerted no effects
in the rCPT paradigm.
Conclusion The MAM-E17 model exhibits robust and repli-
cable impairments in rCPT performance that resemble atten-
tion and inhibitory control deficits seen in schizophrenia.
Pharmacological profiles were highly consistent with known
drug effects on cognition in preclinical and clinical studies.
The rCPT is a sensitive and reliable tool with high translation-
al potential for understanding the etiology and treatment of
disorders affecting attention and executive dysfunction.
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Introduction
Neurological and psychiatric disorders such as schizophre-
nia, attention deficit hyperactivity disorder and Alzheimer’s
disease have profiles of cognitive impairment that are critical
targets for therapeutic remediation. Central to these profiles
are deficits in executive function including impairments in
sustained goal-directed action, attentional and inhibitory
control and regulation of processing speed (Buchanan et al.
1997; Bilder et al. 2000; Knowles et al. 2010). The estab-
lishment of robust preclinical models that appropriately
translate prominent cognitive features of a disorder, along
with the development of valid behavioral assays that are
sensitive to model impairments as well as clinically relevant
treatments, is an important goal for improving cognitive en-
hancement strategies.
A widely used model of neurodevelopmental hallmarks
of schizophrenia involves administration of the mitotic
neurotoxin methylazoxymethanol acetate (MAM) to
pregnant rat dams at gestational day 17. The offspring of
MAM-treated dams (gestational day 17 methylazoxy-
methanol acetate treatment, MAM-E17) show pronounced
neurodevelopmental alterations within limbic and cortical
brain structures (Moore et al. 2006). Histological and electro-
physiological evidence reveals structural and functional dis-
ruptions predominantly within hippocampal and frontostriatal
circuitries in the MAM-E17 model (Gourevitch et al. 2004;
Penschuck et al. 2006; Moore et al. 2006; Lodge and Grace
2008;Matricon et al. 2010; Hradetzky et al. 2012; Gastambide
et al. 2012; Phillips et al. 2012; Snyder et al. 2012). These
disruptions mirror well-established abnormalities in individ-
uals afflicted with schizophrenia: hippocampal and cortical
disorganization including aberrant expression of markers for
inhibitory (Benes et al. 1996; Lewis 2000) and excitatory
(Deakin et al. 1989; Tsai et al. 1995) signaling efficacy and
striatal dopamine (DA) hyperfunction (Abi-Dargham et al.
2000).
The MAM-E17 model also displays several behavioral
characteristics reminiscent of cognitive impairments ob-
served in schizophrenia, including deficits in classic para-
digms such as prepulse inhibition and latent inhibition
(Flagstad et al. 2005; Moore et al. 2006). MAM-E17 rats
show impaired prefrontal cortical-dependent reversal and
extra-dimensional shift learning on a bowl-digging task
(Featherstone et al. 2007; Gastambide et al. 2012) and def-
icits in hippocampal-dependent spatial memory on maze
navigation tasks (Gourevitch et al. 2004; Featherstone
et al. 2009; Gastambide et al. 2015). Impairments in
inhibitory control have also been observed as decreased ef-
ficiency on a differential reinforcement of low-rate (DRL-
20) task and nonsignificant trends toward increased prema-
ture responding in the five-choice serial reaction time task
(5-CSRTT) (Featherstone et al. 2007). Some patients diag-
nosed with schizophrenia show potentially analogous cogni-
tive impairments when challenged with computerized neuro-
psychological tests (Hutton et al. 1998; Birkett et al. 2007;
Leeson et al. 2009; Nuechterlein et al. 2015).
One cognitive paradigm that is particularly sensitive
for detecting reliable impairments in schizophrenia pa-
tients is the continuous performance test (CPT)
(Wohlberg and Kornetsky 1973; Buchanan et al. 1997).
Typical versions of the CPT require subjects to visually
attend to a single location on a monitor and report briefly
presented target stimuli amongst a stream of nontarget
stimuli. Numerous cognitive/executive processes are re-
quired for successful CPT performance including atten-
tion (alerting, selective, or sustained), memory (targets
versus nontargets), inhibitory control (withholding inap-
propriate responses), and processing speed (rapidly iden-
tifying targets). Schizophrenia patients display impair-
ments in the CPT paradigm that appear independent of
symptom severity (Nuechterlein et al. 2015) as well as
clinical (Wohlberg and Kornetsky 1973; Cornblatt et al.
1997) and medication (Cornblatt et al. 1997; Keefe et al.
2006; Nuechterlein et al. 2015) status. Despite consistent
CPT impairments observed in schizophrenia and robust
frontostriatal alterations in MAM-E17 animals, behavioral
effects in the MAM-E17 model using rodent sustained
attention paradigms have been equivocal. Limited evi-
dence of disrupted performance in MAM-E17 rats has
been detected in either the 5-CSRTT (Featherstone et al.
2007) or the sustained attention task (without or including
distractors (SAT/dSAT)) (Howe et al. 2015), even follow-
ing extensive parameter manipulations taxing attentional
and impulsive processes.
The current study implemented a novel touchscreen-
based rodent continuous performance task (rCPT) (Kim
et al. 2015). The rCPT closely emulates the task structure
and main cognitive requirements of common variants of
the human CPT by incorporating a continuous succession
of several luminance-matched target and nontarget images
that require both detection and discrimination as well as
response inhibition on nontarget trials. We hypothesized
that the rCPT might thus be more sensitive for detecting
impairments in attentional and/or executive function in
the MAM-E17 model. We further evaluated the impact
of eight acute systemic treatments of compounds that af-
fect a variety of neurotransmitter systems and have dem-
onstrated potential to enhance cognitive performance in
rodents and/or have efficacy for remediating impairments
in clinical patient groups.
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Methods
Animals
Male offspring of Sprague Dawley rat dams treated on E17
with 24 mg/kg (doses calculated as salt) intraperitoneal
methylazoxymethanol acetate (MAM-E17) or saline (sham)
were generated at Charles River UK, Ltd. (Kent, UK). The
MAM-E17 treatment procedure was similar to that described
by Moore et al. (2006). Offspring were received 12–16 weeks
after birth. Rats were housed in groups of three to four per
cage under a reverse (12 h:12 h) light cycle (lights off at
0700 hours) in a temperature- and humidity-controlled vivar-
ium. After a ≥1-week acclimatization period, the animals’
access to standard diet (standard rat chow; Nestlé Purina,
St. Louis, MO, USA) was restricted. Animals were main-
tained at ≈85–90% of their free-feeding weight throughout
testing. Water was available ad libitum except during operant
testing. The experiments used two cohorts of animals tested
sequentially 1 year apart [cohort 1: MAM (n = 12) and
SHAM (n = 7); cohort 2: MAM (n = 15) and SHAM
(n = 16)]. All experiments were carried out in compliance
with the UK Animals (Scientific Procedures) Act 1986 and
UK Animals (Scientific Procedures) Act 1986 Amendment
Regulations 2012.
Apparatus
The experiments used 18 Med Associates, Inc. modular oper-
ant behavioral chambers (30.5 × 24.1 × 8.25 cm) modified to
include a touch-sensitive monitor (Elo Touch Solutions, Inc.,
Milpitas, CA, USA; see Mar et al. 2013; Oomen et al. 2013)
controlled through in-house software (Visual Basic 2010
Express .NET, Microsoft 2010; developed by A.C.M.). Each
chamber was located within a sound-attenuating box with a
fan installed for ventilation and to mask external noise. The
rear wall of each chamber was equipped with a food magazine
(lower center) connected to a pellet dispenser delivering
45 mg rewards, a tone generator (upper corner), and a house
light (upper center). The food magazine was fitted with a tray
light and a photocell beam detector for recording head entries
and reward collection.
Drugs
Drug dosing protocols were based on both in-house pilot ex-
periments and previously published reports (Waters et al.
2005; Morgan et al. 2007; Redrobe et al. 2012; Prickaerts
et al. 2012; Gastambide et al. 2012).
Sulpiride (Sigma-Aldrich, St. Louis, MO, USA), a dopa-
mine D2/D3R antagonist, was mixed in sterile saline and ad-
ministered intraperitoneally (i.p.) at 0, 1, 3, and 10 mg/kg
doses. Sulpiride has been demonstrated to reduce certain
positive and negative symptoms of schizophrenia but appears
to have limited efficacy against the cognitive impairments of
the disorder (Soares et al. 2000).
Atomoxetine hydrochloride (Sigma-Aldrich, St. Louis,
MO, USA), a noradrenaline reuptake inhibitor (Wong et al.
1982), was mixed in sterile saline and injected i.p. at 0, 0.1,
0.3, and 1.0 mg/kg doses. Atomoxetine can improve certain
attentional measures in individuals with ADHD (Chamberlain
et al. 2007; Maziade et al. 2009; Barry et al. 2009) as well as
response inhibition in healthy volunteers (Chamberlain et al.
2006).
LSN2463359 (Eli Lilly & Co., Ltd., Windlesham, UK), a
mGlu5R positive allo steric modulator (PAM), was suspended
in 1% carboxymethyl cellulose, 0.25% Tween 80, and 0.05%
antifoam and administered per os (p.o.) via syringe at 0, 1.0,
2.5, and 5.0 mg/kg doses. LSN2463359 has been demon-
strated to restore cognitive inflexibility deficits in the
MAM-E17 model (Gastambide et al. 2012).
RO4938581 (F. Hoffmann La Roche, Ltd., Basel,
Switzerland), an inverse agonist at the GABA(A)α5R, was
suspended 0.3% Tween 80 and 0.05% antifoam and adminis-
tered p.o. via gavage at 0, 0.1, 1.0, and 10.0 mg/kg doses.
RO4938581 improves learning and memory in several rodent
models (Ballard et al. 2009; Redrobe et al. 2012).
Modafinil (microionized; Eli Lilly &Co., Ltd., Windlesham,
UK), an atypical stimulant and vigilance promoter, was
suspended in 10% (w/v) sucrose and administered p.o. via sy-
ringe at 0, 8, 32, and 64 mg/kg doses. Modafinil has cognitive-
enhancing and vigilance-promoting properties in various psy-
chiatric disorders (Randall et al. 2004, 2005; Turner et al. 2004;
Hunter et al. 2006; Dean et al. 2011; Schmaal et al. 2013).
ABT-594 (AbbVie, Inc., IL, USA), a potent agonist at
the α4β2nAChR (Donnelly-Roberts et al. 1998), was
mixed in sterile saline and injected i.p. at 0, 1.9, 5.9,
and 19 μg/kg doses. ABT-594 has been shown to improve
aspects of performance on preclinical, sustained attention
tasks (McGaughy et al. 1999; Mohler et al. 2010; Howe
et al. 2010).
Donepezil hydrochloride (Sigma-Aldrich, St. Louis, MO,
USA), an acetylcholinesterase inhibitor, was mixed in sterile
saline and injected i.p. at 0, 0.1, 0.3, and 1.0 mg/kg doses.
Donepezil can improve attentional measures in individuals
with Alzheimer’s disease (Sahakian and Coull 1993; Foldi
et al. 2005).
EVP-6124 (EnVivo Pharmaceuticals, Inc., Watertown,
MA, USA), a partial α7nAChR agonist, was suspended in
10% sucrose in deionized water vehicle and administered
p.o. via syringe at 0, 0.3, 1.0, and 3.0 mg/kg doses. EVP-
6124 showed some indications for therapeutic potential
(Olincy et al. 2006; Freedman et al. 2008; Lieberman
et al. 2013; Preskorn et al. 2014) but failed to show
cognitive-enhancing effects in larger clinical trials
(Fidler 2016).
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Behavioral procedure
Initial training on the rCPT was comprised of four stages. In
the first stage, rats were trained to attend, approach, and touch
a solid white square stimulus (7 × 7 cm) presented centrally on
the touchscreen. Each white square stimulus was presented for
a maximum of 10-s stimulus duration (SD). A 2-s inter-stim-
ulus interval (ISI) was given between stimulus presentations
in which only a white frame outlining the location of the
response window was visible. Screen touches made within
the response window either while the stimulus was being pre-
sented or in less than 500ms following stimulus removal (SD +
500 ms = limited hold (LH) period) were designated as hits
(correct responses). Following hits, the stimulus (if present)
was removed immediately from the screen, the magazine light
was illuminated, and a single 45 mg food reward pellet was
delivered to the magazine. Reward collection extinguished the
magazine light and initiated the next trial ISI. Screen touches
within the response window during the ISI reset the interval,
thus delaying the onset of the next stimulus presentation.
Stimuli that were not touched within the LH period were clas-
sified as misses (stimulus omissions). Sessions were 45–60 min
in duration. Criterion for phase 1 was defined as earning 100
rewards within a session across two consecutive sessions.
In stage 2, the white square was replacedwith a novel target
(S+) stimulus and the SDwas reduced to 2 s (LH = 2.5 s). The
new S+ was either a horizontal or vertical line stimulus,
counterbalanced across both MAM and SHAM groups.
Additionally, a brief ingestion delay (ID) period of 5 s was
introduced following reward collection to permit the animal
time to consume the food pellet before re-engaging in the task.
The ISI prior to the next stimulus began immediately after
termination of the ID. Animals were trained for one to two
sessions on stage 2.
In stage 3, a novel nontarget (S-) stimulus was introduced to
the stimulus set. The new S− was either a vertical or horizontal
line stimulus—whichever was different from the S+ that was
counterbalanced and randomly assigned in stage 2. The SD of
both S+ and S− stimuli was equated at 2 s (LH= 2.5 s), and there
was a 50% probability of either stimulus appearing on any given
normal trial. The ISI was increased to 5 s in stage 3. Touching
the S− stimulus during the LH period was designated as a false
alarm (incorrect response) and resulted in immediate removal of
the stimulus (if present) and initiation of a correction-trial ISI.
On all correction trials, the S−was the only stimulus presented.
These correction trials were introduced for a similar reason as
the inclusion of ISI touch resetting (see stage 1—to discourage
nonselective responding to stimuli and the central screen when
the target stimulus is absent). Withholding responses to the S−
during the LH period was designated as a correct rejection and
initiated a normal-trial ISI. All other parameters were identical
to those of stage 2. Animals were trained for seven to eight
sessions on stage 3.
A flowchart overview of the rCPT trial structure for the
fourth and final training stage is depicted in Fig. 1a. In this
stage, three additional S– stimuli were introduced to the stim-
ulus set. All stimuli were luminance matched in an attempt to
equate their salience for simple brightness detection. The SD
of S+ and S– stimuli was set to be variable (0.5–1.5 s) but with
a fixed LH of 2 s. The LH remained at 2 s after stimulus onset
to maintain the average event rate and to ensure that animals
had equal opportunity to respond to each stimulus. As with
stage 3, the probability of presentation of either an S+ or an S–
stimulus on normal trials was equal (50%). The ISI was also
set to be variable (3–7 s). The variable SD and ISI were intro-
duced to increase the attentional load of the task. Other pa-
rameters were the same as stage 3, with touches to any of the
S– stimuli resulting in a correction trial in which an S– was
presented randomly from the set of four. All animals were
trained a minimum of 20 sessions on stage 4 to establish
reliable rCPT performance prior to drug testing. Animals were
trained on the rCPT for daily sessions, 5–7 days a week.
Experimental design: drug testing
The effects of different compounds were investigated using
stage 4 performance parameters. Drugs were administered fol-
lowing a diagram-balanced Latin square design (Cardinal and
Aitken 2006). Each drug Latin square experiment consisted of
four test sessions with one dose per session. Each dosing ses-
sion was separated by at least 48 h with no-drug baseline ses-
sions run in between. A typical minimum interval of 1 week,
with several no-drug baseline retention sessions being run, was
given between different drug treatments. The order of the drugs
administered to the two cohorts is illustrated in Fig. 1b. In
cohort 1, the effects of EVP-6124, LSN2463359, modafinil,
and RO4938581 were examined on rCPT performance. The
session duration was 60 min in cohort 1 but was restricted
to 45 min in cohort 2 as it had been determined that the
additional 15 min did not greatly alter the pattern of rCPT
results. In cohort 2, RO4938581, donepezil, ABT-594,
atomoxetine, and sulpiride were tested. RO4938581 was
assessed in both cohorts to control for cross-batch reproduc-
ibility of pharmacological effects. Prior to the Latin square
experiment for ABT-594, a preliminary dose (19 μg/kg)
was administered in a crossover design during rCPT testing
to permit acclimation to the initial effects of the drug
(Mohler et al. 2010). All compounds were administered
30 min prior to rCPT testing.
Data analysis
Only the first 45 min of each session was analyzed to
better compare data across cohorts. However, no signif-
icant differences in performance variables were observed
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regardless of whether a 45- or 60- min session was
analyzed in cohort 1.
Behavioral parameters Analogous to human CPTs, a re-
sponse to the target (S+) was classified as a hit, failure to
respond to the target was classified as a miss, withholding
from responding to a nontarget (S–) was recorded as a
correct rejection (CR), and responding to a nontarget
was classified as a false alarm. Responses to the screen
during the ISI (when no stimulus was present) were coded
as ISI touches. For each animal, hit rate (HR) was calcu-
lated as the number of hits as a proportion of the total
number of CS+ presentations (hits / (hits + misses).
False alarm rate (FAR) was calculated as the number of
false alarms as a proportion of the total number of CS–
presentations (FA / (FA + CR)). The discrimination
sensitivity index was calculated as (Macmillan and
Creelman 2004)
d
0 ¼ z hit rateð Þ−z false alarm rateð Þ
with higher values indicating better discrimination sensitiv-
ity across the session. The response criterion was calculated as
c ¼ −0:5 z hit rateð Þ þ z false alarm rateð Þð Þ
with larger values indicating decreased overall responding to
both the target and nontarget stimuli. An identical pattern of
significant effects was obtained when nonparametric indices
of sensitivity and response bias were calculated (Stanislaw and
Todorov 1999), which do not depend on assumptions such as
normal distributions and equal variances for the discriminability
a
b
Fig. 1 Trial structure of the rCPT and timeline of drug administration for
the two cohorts of MAM-E17 and sham control rats. a Schematic dia-
gram of the trial structure of the rCPT. Each session consists of a series of
trials. Each trial begins (see Trial Starts box) with a variable inter-
stimulus interval (ISI) = 3–7 s in which no stimuli are present. A response
to the screen during the ISI is coded as an ISI touch and reinitiates the ISI.
Following the complete ISI, either a designated target stimulus (S+) or
one of four nontarget stimuli (S–) is presented individually within a cen-
tral response window on a touch-sensitive monitor. Each stimulus is pro-
grammed to have a variable stimulus duration (SD) = 0.5–1.5 s. On
normal trials, if an S+ is displayed, a touch to the response window
during a limited hold period following stimulus onset (LH = 2 s) is clas-
sified as a hit and leads to removal of the visual stimulus and reward
delivery. Following reward collection, the normal-trial ISI prior to the
next stimulus is initiated after a brief ingestion delay (ID) = 5 s that affords
the animal time to consume the reward. Failure to respond to the S+
stimulus within the LH is recorded as a miss and initiates the next nor-
mal-trial ISI. If an S– is displayed, omitting a response within the LH is
classified as a correct rejection and initiates the next normal-trial ISI. A
response-window touch during the LH of S– presentation is classified as a
false alarm and causes removal of the visual stimulus and onset of a
correction-trial ISI. Correction trials—in which a randomly selected S–
is presented—are repeated until a successful correct rejection is complet-
ed. b Timeline illustrating the order of the drug administration studies in
cohorts 1 and 2 of MAM-E17 and sham control rats
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of targets and nontargets. The primary dependent variables were
sensitivity index (d′), response criterion (c), hit rate, false alarm
rate, and ISI touches. Correct response latency, incorrect re-
sponse latency, and reward retrieval latency were also assessed.
Independent sample t tests were used to compareMAM and
sham performance in stage 1 (sessions to criterion), stage 2
(average hit rate), and stage 3 (d′). To assess the robustness
of stage 4 rCPT performance in MAM and sham control ani-
mals, the average performance of two to three drug-free base-
line sessions for each measure was analyzed at time points
immediately prior to each Latin square experiment. Only four
of five of the equivalent time points were analyzed in cohort 2
for comparison with cohort 1. A three-way mixed ANOVA
was used in which cohort [1, 2] and group [MAM, sham] were
included as between-subjects factors and time point [1, 2, 3, 4]
was included as a within-subjects factor. To further examine
the stability of the MAM versus sham differences, each cohort
was also analyzed separately at each time point from cohorts 1
and 2 with group as a factor. Effect sizes for the difference in d′
between MAM and sham rats at each time point were also
calculated. The vehicle treatment trials from each Latin square
experiment were also analyzed in a similar manner.
Data from each drug experiment were analyzed using re-
peated measures ANOVA, with group (between-subjects, two
levels of dose: sham versus MAM treatment) and drug dose
(within-subjects, four levels of dose) as independent variables.
Significant main effects of drug were followed by post hoc
comparisons against vehicle using the Šidák adjustment for
multiple comparisons. Significant interactions were investigat-
ed further by analysis of simple main effects and Šidák-
corrected pairwise comparisons. Data were analyzed using
SPSS Statistics 21 (IBM Corp., Armonk, NY, USA). We addi-
tionally confirmed all of our repeatedmeasures ANOVA results
using an alternate statistical model (replicated Latin square de-
sign with a between-subjects factor) that accounted for day and
order effects (Cardinal and Aitken 2006). Moreover, we found
no significant differences in our results when correction trials
were either included or excluded from the analysis.
Results
Effect of MAM-E17 on rCPT performance
Across the two cohorts of animals and eight drug studies
spanning several months, the MAM-E17 rats showed several
highly consistent and selective differences in rCPT perfor-
mance relative to sham controls (Fig. 2d, Table 1). During
Fig. 2 rCPT acquisition data and long-term stability of baseline task
performance in MAM-E17 and sham control animals. a Stage 1 no dif-
ferences between MAM-E17 and sham groups on the number of sessions
to criterion. b Stage 2 no differences between MAM-E17 and sham
groups on mean hit rate. c Stage 3 no differences between MAM-E17
and sham animals on performance sensitivity, d′, averaged across the last
3 days of testing. d Stage 4 mean d′ in the rCPT at four baseline time
points for cohorts 1 and 2. Each time point comprises two to three ses-
sions prior to commencing a Latin square drug study. MAM-E17 rats
show stable deficits in d′ across the four time points spanning several
months. There were no significant effects of cohort or cohort × group
interactions. Data are expressed as mean ± SEM. Hash tags denote sig-
nificant main effects of group (#p < 0.05; ##p < 0.01)
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rCPT acquisition, there were no significant differences be-
tween MAM and sham control rats or between cohorts 1 and
2 in terms of the number of sessions to criterion in stage 1
(Fig. 2a), the hit rate or number of pellets earned per session
during stage 2 (Fig. 2b), or the sensitivity (d′) during stage 3
(Fig. 2c). However, when examining stage 4 rCPT perfor-
mance across baseline sessions prior to each Latin square drug
study, MAM animals exhibited significantly decreased d′
(Fig. 2d; F[1,46] = 15.815, p < 0.001) and significantly in-
creased false alarm rate (F[1,46] = 18.160, p < 0.001) and
number of ISI screen touches (F[1,46] = 7.030, p = 0.011)
relative to sham controls in both cohorts 1 and 2. There were
no significant main effects of cohort or group × cohort inter-
actions for any of the measures, suggesting that the MAM-
E17 model induced specific and robust performance differ-
ences in the rCPT relative to sham controls. When each cohort
and time point was analyzed separately, the effects on both d′
and false alarm rate were significant at three of four time points
in cohort 1 (all p values <0.05) and at every time point in cohort
2 (all p values <0.05), highlighting the stability of the observed
differences between MAM-E17 and sham rats across many
months. The effect sizes of the differences in d′ between
MAM-E17 and shams at each time point were large, ranging
from 0.68 to 1.34 in cohort 1 (overall = 1.23) and from 1.10 to
1.37 in cohort 2 (overall = 1.27).
A similar pattern was observed when measures were aver-
aged across only the vehicle treatment sessions in both cohorts
(four and five sessions in cohorts 1 and 2, respectively). MAM-
E17 rats showed significantly lower performance sensitivity, d′,
relative to sham control animals (F[1,46] = 13.480, p = 0.001).
In addition, MAM-E17 rats displayed significantly higher FAR
(F[1,46] = 13.189, p = 0.001) and ISI touches (F[1,46] = 7.746,
p = 0.008). There were no MAM-E17 effects on any other
measures (HR, c, as well as correct, incorrect, and reward col-
lection latencies). There were no significant main effects of co-
hort or group × cohort interactions for any of themeasures, again
suggesting that the observed effects of the MAM-E17 model on
rCPT performance were specific, stable, and reproducible.
Effect of acute drug treatments on rCPT performance
All of the drug effects on the primary rCPT performance in-
dices (d′, HR, FAR, c, and ISI touches) are presented in
Figs. 3, 4, and 5 and summarized in Table 2 and
Supplementary Table S1. Latency measures (correct response,
incorrect response, and reward collection latency) are present-
ed in Table 3. Only significant and near-significant effects are
highlighted below. Results on nonsignificant measures are
included in the Supplement.
Sulpiride Sulpiride (0–30 mg/kg) dose-dependently and se-
lectively reduced the elevated FAR of MAM animals on the
rCPT (Fig. 3b, Table 2). It also dose-dependently lowered over-
all levels of responding (increased c with decreased HR, FAR,
and ISI touches) and increased correct response latency (Fig.
3a, b, Table 3). One sham animal was excluded from analysis
due to a data acquisition error during the vehicle dose session.
For FAR, there was both a significant main effect of dose
(dose: F[3,84] = 10.203, p < 0.001; H-F corrected) and a sig-
nificant dose × group interaction (dose × group:
F[3,84] = 4.119, p = 0.016; H-F corrected). Post hoc tests
confirmed that sulpiride significantly reduced FAR selectively
in MAM-E17 animals at the highest 30 mg/kg dose relative to
vehicle (p < 0.05), such that MAM-E17 animals no longer
displayed significantly elevated FAR relative to sham controls
at the 30 mg/kg dose (p = 0.206 where p < 0.05 at all other
sulpiride doses). There were no significant FAR changes in
sham control animals under sulpiride treatment. There were
also significant main effects of sulpiride dose on HR (dose:
F[3,84] = 7.614, p < 0.001; dose × group: F[3,84] = 0.149,
p = 0.900; H-F corrected), c (dose:F[3,84] = 10.921, p < 0.001;
dose × group: F[3,84] = 0.994, p = 0.385; H-F corrected), and
ISI touches (dose: F[3,84] = 3.977, p < 0.014; dose × group:
F[3,84] = 0.867, p = 0.450; H-F corrected). Within-subjects
contrasts revealed significant linear relationships between as-
cending sulpiride doses and reductions in HR (F[1,28] = 9.623,
p = 0.004) and ISI touches (F[1,28] = 7.947, p = 0.009), as well
as with increases in c (F[1,28] = 15.014, p < 0.001). Post hoc
tests showed that the highest 30 mg/kg sulpiride dose signifi-
cantly reduced HR and ISI touches and significantly increased
response criterion, c, relative to vehicle-treated animals across
both MAM and sham control groups (all p < 0.05).
There was a significant main effect of sulpiride on correct
response latency (dose: F[3,84] = 8.145, p < 0.001; dose ×
group: F[3,84] = 1.610, p = 0.193), with linear dose-
dependent increases (F[1,29] = 12.451, p = 0.001) such that
the highest 30 mg/kg sulpiride dose resulted in longer correct
response latencies relative to the vehicle treatment (p < 0.05).
Table 1 Summary of the MAM-E17 rat model phenotype relative to
the sham controls on rCPT performance variables
Performance measure MAM-E17 phenotype
Hit rate –
False alarm rate ↑
d′ ↓
c –
ISI touches ↑
Correct latency –
Incorrect latency –
Retrieval latency –
↑ = increased in the MAM-E17 model; ↓ = decreased in the MAM-E17
model; – = not affected in the MAM-E17 model
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Atomoxetine Atomoxetine (0–1 mg/kg) had significant sup-
pressant effects on all of the primary response measures (d′, c,
HR, FAR, ISI touches) and increased correct and incorrect
response latencies in the rCPT (Fig. 3c, d, Tables 2 and 3).
Atomoxetine caused dose-dependent decreases in perfor-
mance sensitivity, d′ (dose: F[3,87] = 2.896, p = 0.040; dose
× group: F[3,87] = 0.408, p = 0.748), HR (dose:
F[3,87] = 11.517, p < 0.001; dose × group: F[3,87] = 0.533,
p = 0.661), FAR (dose: F[3,87] = 6.796, p < 0.001; dose ×
group: F[3,87] = 0.483, p = 0.695), and ISI touches (dose:
F[3,87] = 8.729, p < 0.001; dose × group: F[3,87] = 1.830,
p = 0.148). It also significantly increased response criterion, c
(dose: F[3,87] = 12.473, p < 0.001; dose × group:
F[3,87] = 0.462, p = 0.709).Within-subjects contrasts revealed
significant linear effects on all of these measures, showing that
increasing atomoxetine doses were associated with decreases
Fig. 3 Effect of sulpiride, atomoxetine, LSN2463359, and RO4938581
on rCPT performance inMAM-E17 and sham control rats. All significant
group differences are relative to sham controls, and significant drug ef-
fects are in comparison to the vehicle treatment. For all compounds,
MAM-E17 rats exhibited a dose-independent decrease in d′ relative to
shams (a, c, e, g) a, b Sulpiride. a Sulpiride (30 mg/kg) increased re-
sponse criterion (c) in MAM-E17 animals without affecting d′. b
Sulpiride (30 mg/kg) reduced the elevated FAR selectively in MAM-
E17 animals and caused reductions in HR and ISI touches across both
MAM-E17 and sham animals. c, d Atomoxetine. c Atomoxetine in-
creased c at both 0.3 and 1.0 mg/kg doses and reduced d′ at a 1.0 mg/
kg dose. d Atomoxetine decreased HR and d′ at 0.3 and 1.0 mg/kg and
reduced FAR at 1.0 mg/kg. MAM-E17 animals showed a dose-
independent increase in FAR relative to shams. e, f LSN2463359. e
LSN2463359 (5 mg/kg) increased c across both groups of animals.
MAM-E17 animals showed a dose-independent decrease in d′ compared
to shams. f LSN2463359 (5 mg/kg) reduced HR and ISI touches in both
MAM-E17 and sham groups. MAM-E17 animals showed a dose-
independent increase in FAR. g, h RO4938581. g RO4938581 (10 mg/
kg) increased c in both groups of rats. MAM-E17 animals showed a dose-
independent decrease in d′ relative to sham controls. h RO4938581
(10 mg/kg) decreased HR, FAR, and ISI touches in both groups.
MAM-E17 animals showed a dose-independent increase in FAR com-
pared to sham controls. Gray shading with asterisks denotes the main
effect of drug dosewith a significant difference from vehicle.Red shading
with asterisks denotes group × dose interaction with a significant differ-
ence from vehicle (*p < 0.05; **p < 0.01; ***p < 0.0001). Hash tags
denote significant main effects of group (#p < 0.05; ##p < 0.01;
###p < 0.0001)
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in d′ (F[1,29] = 9.033, p = 0.005), HR (F[1,29] = 23.855,
p < 0.001), FAR (F[1,29] = 12.977, p = 0.001), and ISI touches
(F[1,29] = 29.132, p < 0.001), as well as with increases in c
(F[1,29] = 22.471, p < 0.001). Post hoc tests showed that,
relative to the vehicle treatment, the highest 1 mg/kg dose
significantly decreased d′, HR, and FAR and that both 0.3
and 1 mg/kg doses led to significantly fewer ISI touches and
an increased response criterion, c (all p values <0.05).
There were significant main effects of atomoxetine dose on
both correct response latency (dose:F[3,87] = 12.295, p < 0.001;
dose × group:F[3,87] = 0.517, p = 0.672) and incorrect response
latency (dose: F[3,87] = 8.692, p < 0.001; dose × group:
F[3,87] = 2.512, p = 0.075; H-F corrected).Within-subjects con-
trasts revealed significant linear effects indicating a dose-
dependent slowing of correct (F[1,29] = 22.472, p < 0.001)
and incorrect (F[1,29] = 13.772, p < 0.001) response latencies.
Post hoc comparisons showed that the highest 1 mg/kg dose of
atomoxetine resulted in prolonged response latencies relative to
the vehicle treatment (all p values <0.05).
LSN2463359 LSN2463359 (0–5 mg/kg) dose-dependently
reduced levels of rCPT responding, as evidenced by sig-
nificant changes in HR, c, and ISI touch parameters across
both MAM-E17 and sham control groups (Fig. 3e, f,
Tables 2 and 3). Two sham animals did not receive one
of the appropriate LSN2463359 dose levels and were thus
excluded from statistical analysis.
There were significant main effects of LSN2463359 dose
on HR (dose: F[3,45] = 4.893, p = 0.017; dose × group:
F[3,45] = 0.023, p = 0.970; H-F corrected), c (dose:
F[3,45] = 5.729, p = 0.016; dose × group: F[3,45] = 0.357,
p = 0.638; H-F corrected), and ISI touches (dose:
F[3,45] = 3.681, p = 0.019; dose × group: F[3,45] = 0.197,
p = 0.898). Within-subjects contrasts revealed significant pat-
terns such that increasing LSN2463359 doses were linearly
associated with decreases in HR (F[1,15] = 8.291, p = 0.011)
and ISI touches (F[1,15] = 6.921, p = 0.019), as well as with
linear increases in c (F[1,15] = 7.919, p = 0.013). Post hoc
comparisons showed that the highest 5 mg/kg LSN2463359
dose significantly reduced HR and ISI touches and increased
response criterion, c, relative to vehicle-treated animals across
both MAM-E17 and sham control groups (all p values <0.05).
There was also a nonsignificant trend for higher LSN2463359
doses to reduce FAR (dose:F[3,45] = 2.395, p = 0.081; dose ×
group: F[3,45] = 0.159, p = 0.923).
There was a significant dose × group interaction for reward
collection latency (dose: F[3,42] = 2.110, p = 0.144; dose ×
group: F[3,42] = 3.609, p = 0.045; H-F corrected), but post
hoc tests revealed no significant pairwise comparisons.
RO4938581 RO4938581 (0–10 mg/kg) dose-dependently re-
duced overall levels of responding on the rCPT, as indicated by
an increased c parameter; decreased HR, FAR, and ISI touches;
and increased correct response latencies (Fig. 3g, h, Tables 2
and 3). The effects were highly consistent across both cohorts
Fig. 4 Effect of modafinil and ABT-594 on rCPT performance in sham
and MAM-E17-treated rats. All significant group differences are relative
to sham controls, and significant drug effects are in comparison to the
vehicle treatment. a, b. Modafinil. a At 8 mg/kg, modafinil increased d′
selectively in the sham group without affecting d′ in MAM-E17 animals.
At 64 mg/kg, modafinil decreased d′ and response criterion (c) across
both groups. b At 64 mg/kg, modafinil increased FAR and ISI touches
and in both groups. c, dABT-594. c ABT-594 caused group-independent
decreases in c at both 5.9 and 19.4 μg/kg doses. MAM-E17 animals
showed dose-independent reductions in d′ relative to controls. d ABT-
594 (19.4μg/kg) also increased FAR, HR, and ISI touches in both groups.
MAM animals showed dose-independent increases in FAR and ISI
touches.Gray shading with asterisks denotes the main effect of drug dose
with a significant difference from vehicle. Red shading with asterisks
denotes group × dose interaction with a significant difference from vehi-
cle (*p < 0.05; **p < 0.01; ***p < 0.0001). Hash tags denote significant
main effects of group (#p < 0.05; ###p < 0.0001)
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of animals. From both cohorts 1 and 2, four of 27 MAM-E17
rats and one of 23 sham control animals had data missing from
one of the dosing sessions and were thus excluded from statis-
tical analysis.
There were significant main effects of RO4938581 dose on
HR (dose: F[3,129] = 7.553, p < 0.001; dose × group:
F[3,129] = 0.011, p = 0.998), FAR (dose: F[3,129] = 10.134,
p < 0.001; dose × group: F[3,129] = 1.570, p = 0.200), c (dose:
F[3,126] = 9.395, p < 0.001; dose × group: F[3,126] = 0.053,
p = 0.984), and ISI touches (dose: F[3,129] = 7.172, p < 0.001;
dose × group: F[3,129] = 0.845, p = 0.457; H-F corrected).
Within-subjects contrasts revealed significant linear patterns,
with increasing RO4938581 doses associated with reductions
in HR (F[1,43] = 11.533, p = 0.001), FAR (F[1,43] = 28.607,
p < 0.001), and ISI touches (F[1,43] = 23.687, p < 0.001), as
well as with increases in c (F[1,42] = 19.849, p < 0.001). Post
hoc tests showed that, compared to the vehicle treatment, the
highest 10 mg/kg RO4938581 dose significantly reduced HR,
FAR, and the number of ISI touches and increased response
criterion, c, across both MAM-E17 and sham control groups
(all p values <0.001).
There was a significant main effect of RO4938581 dose on
correct response latency (dose:F[3,126] = 4.580, p= 0.004; dose
× group: F[3,126] = 0.358, p = 0.783), with a significant within-
subjects contrast indicating that ascending doses were linearly
related with increases in correct response latencies
(F[1,42] = 15.055, p < 0.001). Post hoc comparisons showed
that the 10 mg/kg RO4938581 dose significantly increased cor-
rect latencies relative to the vehicle treatment (p values <0.05).
To examine the consistency of RO4938581 effects across
cohorts, the data were analyzed adding cohort as a fixed factor.
Across all dependent measures, there was only a single
Table 2 Summary of
pharmacological effects on the
main rCPT performance variables
Drug Hit rate False alarm rate d′ c ISI touches
Sulpiride ↓ ↓a – ↑ ↓
Atomoxetine ↓ ↓ ↓ ↑ ↓
LSN2463359 ↓ \ – ↑ ↓
RO4938581 ↓ ↓ – ↑ ↓
Modafinil – ↑ ↑ (low dose)b; ↓ (high dose) ↓ ↑
ABT-594 ↑ ↑ – ↓ ↑
Donepezil – – / – –
EVP-6124 – – – – –
↓ = significant decrease; ↑ = significant increase; \ = trend toward decrease; / = trend toward increase; – = no effect
a Effect in the MAM-E17 model only
b Effect in the sham controls only
Fig. 5 Effect of donepezil and EVP-6124 on rCPT performance in sham
and MAM-E17-treated rats. a, b Donepezil. a There was a near-
significant improvement in d′ by donepezil (0.1 mg/kg) across both
groups of animals. MAM-E17 animals exhibited dose-independent de-
creases in d′. b No effects of EVP-6124 on HR, FAR, or ISI touches.
MAM-E17 animals showed a dose-independent increase in FAR. c, d.
EVP-6124. c, d No effects of EVP-6124 on any principal rCPT perfor-
mance indices.Gray-shaded asterisk denotes the main effect of drug dose
with a significant difference from vehicle. Hash tags denote a significant
main effect of group (#p < 0.05; ##p < 0.01)
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significant effect of cohort: a group × dose × cohort interaction
on the response criterion index, c (F[3,120] = 3.791,
p = 0.012), in which sham control animals from cohort 1
had a decreased c parameter when they were administered
1 mg/kg RO4938581 as compared to similarly treated animals
from cohort 2 (p < 0.05). Apart from this isolated effect, there
were no significant main effects of cohort or interactions in-
volving cohort × group, cohort × dose, or cohort × group ×
dose for any of the rCPT performance measures. The general
absence of any statistical effects of cohort on themain findings
of RO4938581 underscores the reliability and reproducibility
of these drug effects on the rCPT paradigm.
Table 3 Response and retrieval latencies of MAM-E17 and sham animals in the rCPT during acute systemic pharmacological challenges
Correct response latency Incorrect response latency Reward retrieval latency
Drug Sham MAM Sham MAM Sham MAM
Modafinil
Vehicle 808 ± 46 827 ± 32 727 ± 48 768 ± 36 1451 ± 118 1424 ± 114
8 790 ± 47 813 ± 25 774 ± 55 746 ± 35 1960 ± 410 1403 ± 128
32 776 ± 59 787 ± 23 727 ± 42 683 ± 15 1460 ± 134 1781 ± 365
64 750 ± 56 788 ± 28 706 ± 37 739 ± 29 1411 ± 147 1442 ± 184
ABT-594
Vehicle 852 ±  31 784 ± 33 649  ± 29 672 ± 30 1531 ± 110 1953  ± 608
1.9 885 ±  35 773 ± 46 661  ± 33 669 ± 36 2096 ± 436 1445  ± 125
5.9 839 ±  35 769 ± 36 694  ± 39 641 ± 28 1555 ± 91 1503  ± 253
19.4 831 ±  35 712 ± 35 691  ± 40 611 ± 32 1633 ± 140 1355  ± 166
LSN2463359
Vehicle 744 ± 71 798 ± 37 665 ± 88 741 ± 35 1454 ± 102 1561 ± 142
1.0 767 ± 84 811 ± 33 767 ± 104 704 ± 25 2316 ± 786 1382 ± 45
2.5 782 ± 88 864 ± 37 784 ± 96 742 ± 28 1468 ± 99 1464 ± 89
5.0 780 ± 95 855 ± 34 766 ± 97 786 ± 26 1625 ± 101 1498 ± 78
RO4938581
Vehicle 874 ± 29 838 ±  26 762 ± 31 722 ± 29 2005 ± 338 4830 ± 3450
0.1 886 ± 27 841 ±  34 715 ± 28 749 ± 32 5205 ± 3324 1887 ± 267
1.0 928 ± 29 850 ±  31 794 ± 28 720 ± 30 2020 ± 382 1610 ± 109
10.0 924 ± 29 897 ±  32 735 ± 26 722 ± 24 3442 ± 1233 4100 ± 1705
Donepezil
Vehicle 871 ± 38 798 ± 37 737 ± 31 670 ± 31 1410 ± 85 1633 ± 228
0.1 857 ± 33 785 ± 35 680 ± 30 683 ± 33 1959 ± 435 1495 ± 144
0.3 823 ± 31 800 ± 48 717 ± 43 711 ± 30 1592 ± 180 1805 ± 320
1.0 867 ± 26 793 ± 52 704 ± 44 689 ± 29 1897 ± 417 1584 ± 171
Atomoxetine 
Vehicle 893 ± 31 815 ± 31 619 ± 39 700 ± 23 1835 ± 371 1654 ± 276
0.1 912 ± 32 814 ± 40 698 ± 35 663 ± 27 2311 ± 535 1621 ± 199
0.3 909 ± 31 861 ± 43 696 ± 40 668 ± 27 2200 ± 580 1490 ± 113
1.0 1006 ± 32 926 ± 42 757 ± 42 791 ± 40 1537 ± 64 1568 ± 103
Sulpiride
Vehicle 918 ± 35 796 ± 36 741 ± 54 691 ± 33 1835 ± 371 1654 ± 276
0.1 908 ± 37 846 ± 37 676 ± 45 684 ± 31 2311 ± 535 1621 ± 199
0.3 892 ± 33 844 ± 33 695 ± 51 737 ± 28 2200 ± 580 1490 ± 113
1.0 977 ± 36 900 ± 33 672 ± 46 705 ± 34 1537 ± 64 1568 ± 103
EVP-6124
Vehicle 868 ± 54 896 ± 44 655 ± 49 670 ± 50 1528 ± 144 1405 ± 104
0.3 901 ± 43 910 ± 37 666 ± 132 726 ± 40 3337 ± 1766 1421 ± 89
1.0 946 ± 65 927 ± 44 477 ± 73 696 ± 40 2187 ± 678 1355 ± 61
3.0 851 ± 70 917 ± 43 720 ± 43 702 ± 46 16,638 ± 15,164 1587 ± 302
For the significant effects of the drug dose denoted by color with statistical significance highlighted by color code, please see the legend
Sig. increase 
from vehicle
0.01
0.001
0.05 Sig. decrease 
from vehicle
p <
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Modafinil Modafinil (8 mg/kg) selectively improved perfor-
mance sensitivity, d′, in sham control rats (Fig. 4a, Table 2).
Modafinil (0–64 mg/kg) also dose-dependently increased
levels of responding within the rCPT, as demonstrated by
decreases in c, increases in FAR and ISI touches, and linear
reductions in correct response latency with increasing
modafinil dose (Fig. 4a, b, Tables 2 and 3).
For performance sensitivity, d′, there was both a significant
main effect of dose (F[3,51] = 4.396, p = 0.008) and a signif-
icant dose × group interaction (F[3,51] = 3.834, p = 0.015).
Post hoc tests confirmed that low-dose (8 mg/kg) modafinil
selectively enhanced d′ in sham control animals (increased d′
relative to sham vehicle, p < 0.05). Post hoc comparisons with-
in the main effect of dose also showed that, relative to vehicle,
the highest 64 mg/kg modafinil dose reduced d′ performance
across both MAM-E17 and sham control animals (p < 0.05).
There were significant main effects of modafinil dose on FAR
(dose: F[3,51] = 12.304, p < 0.001; dose × group:
F[3,51] = 2.152, p = 0.105), c (dose: F[3,51] = 6.511,
p = 0.001; dose × group: F[3,51] = 0.747, p = 0.529), and ISI
touches (dose: F[3,51] = 8.480, p < 0.001; dose × group:
F[3,51] = 0.184, p = 0.907). Within-subjects contrasts revealed
significant linear relationships, with an increasing modafinil
dose associated with increases in FAR (F[1,17] = 35.048,
p < 0.001) and ISI touches (F[1,17] = 17.681, p < 0.001), as
well as a decreases in response criterion, c (F[1,17] = 20.678,
p < 0.001). Post hoc tests showed that, relative to the vehicle
treatment, the highest 64 mg/kg modafinil dose significantly
elevated the FAR and number of ISI touches and decreased c
across all animals (all p values <0.05).
Within-subjects trend analysis also revealed a significant
linear relationship in which higher modafinil doses were asso-
ciated with faster correct response latencies (F[1,17] = 8.367,
p < 0.010).
ABT-594 ABT-594 (0–19.4 μg/kg) dose-dependently in-
creased overall levels of responding by decreasing the c pa-
rameter and increasing HR, FAR, and ISI touches. ABT-594
also dose-dependently decreased correct response latencies
(Fig. 4c, d, Tables 2 and 3).
In the acclimation to ABT-594 dosing using a crossover
design (data not shown), there was a significant group × dose
interaction (F[1,29] = 4.932, p < 0.05) observed for ISI
touches, in which 19.4 μg/kg ABT-594 increased ISI touches
selectively in MAM rats.
In the Latin square, there were significant main effects of
ABT-594 dose on HR (dose: F[3,87] = 5.897, p = 0.001; dose
× group: F[3,87] = 0.422, p = 0.724), FAR (dose:
F[3,87] = 17.807, p < 0.001; dose × group: F[3,87] = 0.238,
p = 0.870), c (dose:F[3,87] = 15.072, p < 0.001; dose × group:
F[3,87] = 0.276, p = 0.842), and ISI touches (dose:
F[3,87] = 13.432, p < 0.001; dose × group: F[3,87] = 2.552,
p = 0.083; H-F corrected). Within-subjects contrasts revealed
significant linear increases in HR (F[1,29] = 13.385,
p = 0.001), FAR (F[1,29] = 42.314, p < 0.001), and ISI
touches (F[1,29] = 26.450, p < 0.001), as well as a significant
linear decrease in c (F[1,29] = 32.801, p < 0.001) in response
to increasing ABT-594 doses. Post hoc comparisons showed
that the highest 19.4 μg/kg ABT-594 dose significantly in-
creased HR, FAR, and ISI touches, and both the 5.9 and
19.4 μg/kg doses decreased response criterion (c) relative to
vehicle-treated animals (all p values <0.05).
ABT-594 dose-dependently speeded correct response la-
tencies (dose: F[3,87] = 4.698, p = 0.004; dose × group:
F[3,87] = 1.362, p = 0.260) where within-subjects contrasts
revealed a linear decrease in latencies across ascending doses
(F[1,29] = 8.606, p = 0.006). Post hoc tests showed that the
highest 19.4 μg/kg dose decreased correct response latencies
compared to the vehicle treatment (p < 0.05). There was a
significant dose × group interaction on incorrect response la-
tency (dose: F[3,87] = 0.309, p = 0.819; dose × group:
F[3,87] = 3.356, p = 0.022), but post hoc tests revealed no
significant pairwise comparisons.
Donepezil There was a strong but nonsignificant trend for
donepezil (0–1 mg/kg) to improve performance sensitivity, d′,
with no impact on any other rCPT measures (Fig. 5a, b,
Tables 2 and 3). One MAM-E17 and one sham rat had missing
data due to computer hardware failure during testing and were
excluded from statistical analysis. There was a trend for a main
effect of donepezil to enhance d′ performance across both
MAM-E17 and sham control rats (dose: F[3,81] = 2.584,
p = 0.064; dose × group: F[3,81] = 1.256, p < 0.295; H-F
corrected). This trend toward performance enhancement was
most pronounced at the lowest 0.1 mg/kg donepezil dose rela-
tive to the vehicle treatment. There were no significant effects
of donepezil on any other performance measure in the rCPT.
EVP-6124 EVP-6124 (0–3 mg/kg) did not alter any perfor-
mance measure in the rCPT (Fig. 5c, d, Tables 2 and 3). One
MAM-E17 animal made no responses at the 0.3 mg/kg dose
and was thus necessarily excluded from statistical analyses of
d′, c, and response latencies. An identical pattern of statistical
results was obtained if the animal was excluded from all
measures.
There was a near-threshold significant main effect of EVP-
6124 dose on correct response latency (dose: F[3,48] = 2.776,
p = 0.050; dose × group: F[3,48] = 1.346, p = 0.270), where
the largest effect was a slower correct response time at the
1 mg/kg dose.
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Discussion
MAM-E17 model impairments on rCPT
MAM-E17 rats showed robust and persistent deficits in dis-
criminative sensitivity (d′) on the rCPT relative to sham con-
trols. The effect size was large, virtually identical in two co-
horts of animals (Cohen’s d = 1.23 and 1.27), and consistent
across repeated drug testing. This model profile is remarkably
similar to impairments on common variants of human CPTs
widely reported in neuropsychiatric disorders such as ADHD
or schizophrenia (Chen and Faraone 2000; Riccio et al. 2002).
For example, a meta-analysis examining CPT performance
across 15 studies reported substantial d′ impairments
(d = 1.18) in schizophrenia compared to control subjects
(Heinrichs and Zakzanis 1998). A large, multi-site study
found similar d′ decrements in schizophrenia on three-digit
(d = 1.13) and four-digit (d = 1.14) identical-pairs CPT
(Nuechterlein et al. 2015). Moreover, several studies have
demonstrated that such d′ deficits may remain stable over time
irrespective of psychotic/remitted state, positive or negative
symptoms or medication status, and are reliable across repeat-
ed testing (Cornblatt et al. 1997; Nuechterlein et al. 2015).
The MAM-E17 deficits in d′ were observed in the absence
of significant changes in response bias/criterion (c). This dis-
sociation between d′ and cmirrors what is commonly reported
in schizophrenia research using CPT (Mussgay and Hertwig
1990; Nuechterlein et al. 2015). Response bias/criterion is
theoretically independent of d′ and defines the extent to which
a particular response type or strategy (e.g., to respond or with-
hold responding) is preferred or more probable (Stanislaw and
Todorov 1999; Macmillan and Creelman 2004). In line with
interpretations of the human CPT literature, the robust and
selective reduction in d′ for the MAM-E17 model may be
attributable to impairments in sustained, focused, and/or se-
lective attentional processes—the ability to maintain readiness
and to detect, discriminate, and respond appropriately to rap-
idly and successively presented target stimuli across time
(Parasuraman 1979; Davies and Parasuraman 1982).
Schizophrenia-related deficits in d′ are frequently reported
in conjunction with decreases in the number or rate of detected
target stimuli (Cornblatt et al. 1989; Nuechterlein et al. 2015).
In the current study, MAM-E17 rats displayed a consistent,
but nonsignificant, decrement in target HR relative to sham
controls. The discrepancy in effect sizes for HR between ro-
dent and human versions might reflect differences in cost/
benefit structure. In the rCPT, there is a high incentive for
animals to maximize target hits (immediate food rewards)
with modest punishment (delay) for occasional errant re-
sponses. MAM-E17 rats might thus compensate for a lower
d′ by slightly adjusting their response strategy (e.g., higher
FAR) to maximize rewards (Lynn and Barrett 2014). By con-
trast, human CPT variants typically offer no immediate incen-
tives to encourage target hits (Locke and Braver 2008). It
would be interesting to examine how systematic alterations
in the cost/benefit matrix of the rCPT or human CPTs alter
the performance of theMAM-E17model and individuals with
schizophrenia, respectively.
The MAM-E17 model also has a profile consistent with
deficits in inhibitory control on the rCPT, showing significant
increases in nontarget FAR and in the number of screen
touches in the absence of any stimuli (ISI touches). General
locomotor hyperactivity of MAM-E17 animals has been re-
ported in several studies (Le Pen et al. 2006; Hazane et al.
2009; Ratajczak et al. 2015; O’Reilly et al. 2016; but see
Flagstad et al. 2004) and discussed as a possible confound in
the assessment of cognitive function (O’Reilly et al. 2016).
However, it is unlikely that excessive, nonspecific motor ac-
tivity of MAM-E17 rats is a large contributing factor to cog-
nitive performance in the rCPT as we observed no significant
group differences on HR, overall response bias/criterion, or
any reaction time latencies. More specific impairments in in-
hibitory control have been proposed based on performance in
other behavioral paradigms: MAM-E17 rats showed an in-
creased number of responses, decreased efficiency and num-
ber of rewards earned on a differential reinforcement of low-
rate (DRL-20) task, as well as a nonsignificant trend to make
more premature responses in the 5-CSRTT (Featherstone et al.
2007). Moreover, the robust pattern of MAM-E17 deficits in
reversal and extra-dimensional shift learning is suggestive of
general impairments in the ability to flexibly inhibit responses
to prepotent or behaviorally salient stimuli (Moore et al. 2006;
Featherstone et al. 2007; Gastambide et al. 2012). Increased
false alarm rates are also frequently reported in schizophrenic
patients (Wohlberg and Kornetsky 1973; Birkett et al. 2007;
Nuechterlein et al. 2015) and are found to be correlated with
negative (Nuechterlein et al. 1986) or disorganized symptom
domains of the disorder (Vollema and Postma 2002).
The observed deficits in attentional and inhibitory response
control on the rCPT are predicted based on the known
neurodevelopmental sequelae of the MAM-E17 model
(Lodge and Grace 2007; Chen et al. 2014; Perez et al. 2014;
Grace 2016; Penschuck et al. 2006; Lodge et al. 2009;
Maćkowiak et al. 2014). However, despite its similarities to
schizophrenia and robust performance impairments on the
rCPT, it is noteworthy that previous studies have not readily
observed specific deficits in attention and executive function
within the MAM-E17 model. Impairments in prepulse inhibi-
tion, latent inhibition, set shifting, and learning or perfor-
mance on spatial tasks are well documented in MAM-E17
animals (Flagstad et al. 2005; Moore et al. 2006;
Featherstone et al. 2007; Gastambide et al. 2012; O’Reilly
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et al. 2016), but owing to factors such as hyperactivity and/or
other behavioral processes, their precise links to attentional
and/or executive control are unclear. Moreover, when the
MAM-E17 model was evaluated on tasks explicitly designed
to be analogous to human CPTs such as the 5-CSRTTor SAT/
dSAT, no significant differences from sham controls were ob-
served on any performance measures (Featherstone et al.
2007; Howe et al. 2015). The present rCPT was designed to
incorporate key parameters that have been demonstrated to tax
attentional and executive control processes in the human CPT
paradigm. These parameters include the successive presenta-
tion of stimuli which demands withholding responses on non-
target trials, as well as the use of visual stimuli that require
both detection and discrimination between target and nontar-
gets matched for overall luminance (Parasuraman 1979; See
et al. 1995). The 5-CSRTT, SAT/dSAT, and related paradigms
do not require withholding responses on any trials and only
require detection and/or localization of luminance increments.
These task differences are likely to engage distinct neural
mechanisms and might help explain the increased sensitivity
of the rCPT to detect impairments in attentional and executive
control in the MAM-E17 model. It should be noted that the
present study examined stable rCPT performance in middle-
aged, male rats to help make it comparable to previous studies
examining attentional and executive performance in the
MAM-E17 model. It would be worthwhile to extend investi-
gations to include female subjects and to assess model differ-
ences at an earlier developmental period—from late juvenile
to young adulthood—which represents a critical time for
schizophrenia onset and which may also provide a better po-
tential window for successful treatment intervention.
Pharmacological effects of psychoactive compounds
Suppressant-like effects (sulpiride, atomoxetine,
LSN2463359, RO4938581)
Acute administration of the D2/D3 receptor antagonist and
neuroleptic, sulpiride (0–30mg/kg); the selective noradrenergic
reuptake inhibitor, atomoxetine (0–1 mg/kg); the mGlu5R
PAM, LSN2463359 (0–5 mg/kg); and the GABA(A)α5R par-
tial inverse agonist, RO4938581 (0–10 mg/kg), each exerted
suppressant-like effects on rCPT performance by dose-
dependently reducing indices of overall responding across all
animals. These reductions were evidenced by an increased re-
sponse criterion, c, and decreased ISI touches, HR, and/or FAR.
Given that incorrect and reward collection latencies were unal-
tered by these compounds, the suppressant effects are unlikely
to be simply attributed to potentially confounding factors such
as motor depression or anhedonia. Moreover, with the excep-
tion of the highest dose of atomoxetine, the general absence of
drug effects on sensitivity (d′) further suggests that the effects
cannot be easily related to changes in sustained, focused atten-
tion or visual discrimination processes.
The suppressant-like effects of these compounds are con-
sistent with numerous prior studies and may suggest that they
are acting to reduce impulsive/motivated responding to salient
cues predictive of reward. Numerous studies have described
D2/D3 antagonist-induced decreases in operant responding
for reward (Harrison et al. 1997; Heath et al. 2015; Froger-
Colléaux and Castagné 2016). Anti-impulsive effects of
atomoxetine have also been widely observed in both rodents
and humans tested on a variety of cognitive paradigms
(Blondeau and Dellu-Hagedorn 2007; Navarra et al. 2008;
Robinson et al. 2008; Paterson et al. 2011; Fernando et al.
2011; Baarendse and Vanderschuren 2011; Robinson 2012;
Chamberlain et al. 2006, 2007; Bari et al. 2009; Tomlinson
et al. 2014).The mGlu5R PAM, ADX47273, has been ob-
served to reduce the number of impulsive responses in normal
healthy rats in the 5-CSRTT (Liu et al. 2008; Isherwood et al.
2015), and RO4938581, as well as several mGlu5R PAMs, has
been demonstrated to reduce hyperactivity observed inmodels
of NMDAr antagonist or psychostimulant administration
(Schlumberger et al. 2010; Bartolomé-Nebreda et al.
2013; Conde-Ceide et al. 2016; Ballard et al. 2009;
Redrobe et al. 2012).
None of these compounds exerted any beneficial effects on
the rCPT performance sensitivity index, d′. For sulpiride, this
is in line with the clinical literature indicating that current
neuroleptic treatment mechanisms do not significantly im-
prove fundamental attentional impairments in schizophrenia
(Cornblatt et al. 1997; Nuechterlein et al. 2015). However,
atomoxetine has enhanced performance accuracy on certain
sustained attention assays, particularly when long and/or var-
iable ITIs have been introduced or manipulated (Jentsch et al.
2008; Baarendse and Vanderschuren 2011; Robinson 2012;
Tomlinson et al. 2014). Cognitive-enhancing effects of
mGlu5R PAMs and GABA(A)α5R receptor-negative alloste-
ric modulators (α5NAMs) have been reported on other tasks
assessing behavioral flexibility, aversive learning, recognition
memory, and working memory in normal, healthy mice and
rats (Darrah et al. 2008; Uslaner et al. 2009; Stefani and
Moghaddam 2010; Fowler et al. 2011; Gilmour et al. 2013;
Dawson et al. 2006; Atack et al. 2006). Moreover,
LSN2463359 (2.5 mg/kg) was observed to selectively restore
impairments in reversal learning and extra-dimensional set
shifting selectively in MAM-E17 rats in a bowl-digging
paradigm (Gastambide et al. 2012). The putative anti-
impulsive properties of these compounds may provide a
parsimonious and testable explanation for the pattern of
nootropic effects on certain other behavioral assays.
Enhancement of task performance by compounds that help
reduce impulsivity might be predicted within experimental
paradigms in which rapid stimulus processing and
responding are not required and where hyperactivity or
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impulsivity in model animals may confound and/or impair
performance.
We observed detrimental effects of higher-dose (1.0 mg/
kg) atomoxetine on d′. Such impairments may be predicted
by inverted-U theories of catecholamine function (Aston-
Jones and Cohen 2005; Robbins and Arnsten 2009) and have
also been observed in primates in a working memory task
(Gamo et al. 2010) and a decision-making task in rodents
(Silveira et al. 2016). The novel features of the rCPT relative
to other rodent attentional paradigms may render it more de-
manding and more sensitive to detrimental effects of higher
doses of pro-catecholaminergic agents.
Sulpiride was the only drug to selectively alter rCPT per-
formance of MAM-E17 animals by dose-dependently reduc-
ing their elevated false alarm rate. This result fits well with
findings that sulpiride treatment can specifically remediate
dysfunctional plasticity within hippocampal and frontostriatal
circuitry of MAM-E17 rats (Belujon et al. 2013; Belujon et al.
2014). Moreover, antagonism of dopamine D2 and/or D3 re-
ceptors in the nucleus accumbens core has been demonstrated
to selectively improve inhibitory control in other model ani-
mals (medial prefrontal cortex (mPFC) lesioned, amphet-
amine injected, or selected high-impulsive animals) that ex-
hibit high levels of impulsivity on the 5-CSRTT (Pattij et al.
2006; Pezze et al. 2008; Besson et al. 2010). Systemic D2/D3
antagonism may reduce motivational salience for stimuli and
responses governing rCPT performance (Treadway and Zald
2013) and preferentially remediate an inhibitory control defi-
cit in MAM-E17 animals that may result from aberrant
frontostriatal-based salience mechanisms, as hypothesized
for schizophrenia (Kapur 2003).
Stimulant-like effects (modafinil, ABT-594)
The eugeroic agent, modafinil (8 mg/kg), was the only com-
pound to cause significant improvements in sensitivity, d′, a
common index of sustained, focused attentional performance
in the CPT paradigm, but did so only in control rats. Modafinil
has shown mixed effects for cognitive enhancements in
healthy human subjects but generally improves performance
on tests of sustained and focused attention at more difficult
task parameters using low to moderate doses (Scoriels et al.
2013; Battleday and Brem 2015). While the majority of stud-
ies using young, healthy rodents in the 5-CSRTT has found
either no effect or reductions in attentional accuracy and/or
inhibitory control (Milstein et al. 2003; Waters et al. 2005;
Liu et al. 2010), such results may be explained by the use of
higher dose ranges (>30 mg/kg) and/or insufficient task diffi-
culty. We also found that higher doses of modafinil in the
rCPT increased FAR and ISI touches, decreased criterion (c),
and a significant linear trend toward faster correct response
latencies across all animals. Together with our observed im-
pairments in d′ at the 64 mg/kg dose, these results suggest that
the stimulant effects of modafinil at higher doses might be
subject to a speed/accuracy tradeoff and be detrimental to task
performance. Indeed, higher doses of modafinil (64–128 mg/
kg) have been reported to induce locomotor hyperactivity in
rats (Simon et al. 1995; McClellan and Spencer 1998). Similar
to our rCPT results, low-dose modafinil (10 mg/kg) has been
observed to improve performance on a stop signal reaction
time task specifically in low-performing rats, while impairing
behavior at higher 100 mg/kg doses (Eagle et al. 2007).
Moreover, one study has reported an enhancement in atten-
tional accuracy following repeated daily dosing of modafinil
(8–64 mg/kg) in older rats having low baseline performance
levels on a three-stimulus detection task with variable stimu-
lus durations and inter-trial intervals (Morgan et al. 2007).
Thus, both the lower dose (8 mg/kg) and the increased diffi-
culty of the rCPT over the 5-CSRTT (e.g., variable stimulus
durations and ITIs, plus discrimination versus simple detec-
tion) may have rendered it more sensitive for detecting the
attention-enhancing effects of modafinil.
It is unclear why modafinil enhanced sham performance
but was ineffective within the MAM-E17 model. One possi-
bility is that disruptions of mPFC structure and function
(Grace 2016), a brain region consistently implicated in suc-
cessful CPT performance (Rosvold et al. 1956; Glosser and
Goodglass 1990; Carter et al. 1998), might preclude the drugs’
beneficial effects. Modafinil has been demonstrated to in-
crease dopamine levels (de Saint Hilaire et al. 2001) and ac-
tivity (Gozzi et al. 2012) within the mPFC of the rat and to
alter PFC activity during cognitive demand in humans (Rasetti
et al. 2010; Minzenberg et al. 2010). Interestingly, although
modafinil has been found to improve aspects of executive
control (Turner et al. 2004), it has generally not been found
to rectify sustained attentional deficits in schizophrenia (Sevy
et al. 2005; Freudenreich et al. 2009; Kane et al. 2010).
Further investigation into the mechanisms of modafinil on
attention is warranted.
The selective α4β2nAChR agonist ABT-594 exerted
stimulant-like effects on HR, FAR, c, ISI touches, and cor-
rect response latency across both groups of animals on the
rCPT. Stimulant effects of α4β2 agonists have been ob-
served in a variety of tasks including locomotor activity
(Bannon et al. 1998) and the 5-CSRTT (Grottick and
Higgins 2000; Hahn et al. 2003; Mohler et al. 2010). We
did not see any ABT-594-related improvements in d′, which
suggests that the drug is not augmenting the sustained ca-
pacity to correctly discriminate target from nontarget stimuli.
However, our observed increases in HR and rewards earned
and decreases in correct response latency are potential indi-
ces of cognitive enhancement and consistent with effects
observed in other attentional paradigms. Improvements in
response accuracy, total correct, and speeded correct reaction
times have also been observed under specific conditions
within the 5-CSRTT and SAT/dSAT paradigms following
Psychopharmacology
α4β2nAChR agonist treatment (McGaughy et al. 1999;
Mohler et al. 2010; Howe et al. 2010). This pattern of results
might be due to α4β2 agonists acting to lower the threshold
for go responses to visually detected stimuli (presence or
absence of light). This hypothesis would explain the selec-
tive improvements in performance accuracy on detection
tasks only when baseline performance is low. Moreover, as
d′ on the rCPT requires sustained attention for both visual
discrimination and visual detection processes, it may be that
the former is not improved by nicotine or α4β2nAChR ag-
onists. This interpretation might also fit with human studies
showing faster responding but inefficacy of nicotine against
the sustained attention deficits induced by ketamine in
humans (D’Souza et al. 2012) and failure of the
α4β2nAChR agonist AZD3480 to improve sustained atten-
tion in schizophrenic patients when visual discrimination
processes are required (Velligan et al. 2012).
Compounds with limited effects on rCPT performance
(donepezil, EVP-6124)
We observed no significant effects of the cholinesterase inhib-
itor, donepezil (0–1.0 mg/kg), on any measure of rCPT per-
formance in MAM-E17 or sham controls. This result is con-
sistent with recent reviews and large meta-analyses, suggest-
ing that the impact of donepezil on sustained attentional per-
formance in schizophrenia is equivocal (Singh et al. 2012;
Thakurathi et al. 2013; Choi et al. 2013). There are also lim-
ited effects of donepezil on attention in healthy individuals
(Beglinger et al. 2004). Our data did, however, show a near-
significant effect of donepezil dose on d′ across all animals
(p = 0.064)—strongest at the lowest 0.1 mg/kg dose—but also
show mean improvements at 0.3 and 1.0 mg/kg relative to
vehicle. Donepezil is known to enhance behavioral contrast
sensitivity, particularly within sensitive spatial frequency
ranges (Soma et al. 2013). Moreover, we have recently ob-
served that donepezil can enhance d′ of DBAmice in the rCPT
paradigm, specifically on more difficult, shorter-stimulus du-
rations (Kim et al. 2015). The enhancing effects of donepezil
on sustained and focused visual attention may thus depend
critically on the visual capacity of the subject and the visual
properties of the stimuli used. It would be worthwhile to ex-
amine the effects of donepezil or other pro-cholinergic com-
pounds both in the MAM-E17 model and in schizophrenia
patients using a CPT-like paradigm in which task parameters
such as contrast, spatial frequency, and stimulus duration are
expressly manipulated.
The partial α7nAChR agonist, EVP-6124 (0–3.0 mg/kg),
did not affect rCPT performance in sham controls or MAM-
E17 animals. There has been much clinical interest around the
therapeutic potential of α7nAChR stimulation (Garay et al.
2016), and one recent study showed that EVP-6124 (1.0 mg/
kg) improved attentional control selectively in a low-
performing subgroup of rats using the 5C-CPT (Hayward
et al. 2017). However, acute α7nAChR administration gener-
ally does not affect rodent attentional performance as measured
by the 5-CSRTT (Grottick et al. 2003; Hahn et al. 2003; Hoyle
et al. 2006; Nilsson et al. 2016). Moreover, α7nAChR agonists
have repeatedly demonstrated nonsignificant effects on
sustained attention in individuals with schizophrenia (Olincy
et al. 2006; Freedman et al. 2008; Lieberman et al. 2013;
Preskorn et al. 2014; Umbricht et al. 2014). EVP-6124 has
recently failed a phase III trial with the endpoint of improved
cognitive function in schizophrenia due to a lack of efficacy
(Fidler 2016). Thus, our lack of enhancing effects of EVP-6124
on attention and executive function appears to be in general
agreement with the bulk of preclinical and clinical findings.
Summary and conclusions
MAM-E17 rats show a robust and reproducible pattern of
deficits on a novel touchscreen continuous performance test
that closely mirrors impairments observed in schizophrenia
and other disorders (Table 1). The specific deficits in sustained
attention/executive control found using the rCPT paradigm
are predicted based on underlying neurobiological disruptions
in the MAM-E17 model yet are the first to be unambiguously
detected within a rodent behavioral paradigm.
The eight acutely administered compounds tested in this
study each exhibited distinct behavioral profiles on rCPT per-
formance variables as summarized in Table 2. Sulpiride,
atomoxetine, LSN2463359, and RO493858 each showed sup-
pressant effects on rCPT performance, including increases in
response criterion (c) and decreases in ISI touches and HR
and/or FAR. Conversely, modafinil and ABT-594 exerted
stimulant-like effects with decreases in c and increases in ISI
touches, HR, and/or FAR. Donepezil showed near-significant
enhancements in d′, and EVP-6124 exerted no effects on the
rCPT. In terms of model-specific drug effects, sulpiride dose-
dependently reduced the elevated FAR in MAM-E17 rats
whereas low-dose modafinil (8 mg/kg) improved d′ only in
sham controls. These drug profiles are largely consistent with
the human and rodent literatures using similar attentional par-
adigms and highlight their observed general lack of effective-
ness for selectively improving d′ in schizophrenia. The rCPT
may be an important translational test for the human CPT
paradigm, which is one of the most widely used tools for the
assessment of sustained and focused attention and executive
function in clinical neuropsychometrics.
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